vs
EXACT SCIENCES CORP（EXAS）与STIFEL FINANCIAL CORP（SF）财务数据对比。点击上方公司名可切换其他公司
STIFEL FINANCIAL CORP的季度营收约是EXACT SCIENCES CORP的1.3倍（$1.1B vs $878.4M），STIFEL FINANCIAL CORP净利率更高（23.5% vs -9.8%，领先33.2%），EXACT SCIENCES CORP同比增速更快（23.1% vs 23.0%），STIFEL FINANCIAL CORP自由现金流更多（$369.0M vs $120.4M），过去两年STIFEL FINANCIAL CORP的营收复合增速更高（21.1% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
司迪富金融是美国跨国独立投资银行及金融服务提供商，总部位于密苏里州圣路易斯市中心。其历史可追溯至1890年成立的Altheimer & Rawlings投资公司，1983年正式以Stifel为名成立，1986年11月24日在纽约证券交易所挂牌上市，为全球客户提供多元化金融服务。
EXAS vs SF — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $264.4M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 27.3% |
| 净利率 | -9.8% | 23.5% |
| 营收同比 | 23.1% | 23.0% |
| 净利润同比 | 90.1% | 8.3% |
| 每股收益（稀释后） | $-0.45 | $2.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | $962.6M | ||
| Q2 25 | $811.1M | $838.9M | ||
| Q1 25 | $706.8M | $842.5M | ||
| Q4 24 | $713.4M | $916.0M | ||
| Q3 24 | $708.7M | $810.9M | ||
| Q2 24 | $699.3M | $798.9M | ||
| Q1 24 | $637.5M | $768.1M |
| Q4 25 | $-86.0M | $264.4M | ||
| Q3 25 | $-19.6M | $211.4M | ||
| Q2 25 | $-1.2M | $155.1M | ||
| Q1 25 | $-101.2M | $53.0M | ||
| Q4 24 | $-864.6M | $244.0M | ||
| Q3 24 | $-38.2M | $158.5M | ||
| Q2 24 | $-15.8M | $165.3M | ||
| Q1 24 | $-110.2M | $163.6M |
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
| Q4 25 | -9.4% | 27.3% | ||
| Q3 25 | -3.0% | 29.7% | ||
| Q2 25 | -0.3% | 25.5% | ||
| Q1 25 | -13.6% | 7.5% | ||
| Q4 24 | -122.8% | 29.1% | ||
| Q3 24 | -5.6% | 26.7% | ||
| Q2 24 | -3.8% | 28.4% | ||
| Q1 24 | -16.7% | 28.5% |
| Q4 25 | -9.8% | 23.5% | ||
| Q3 25 | -2.3% | 22.0% | ||
| Q2 25 | -0.1% | 18.5% | ||
| Q1 25 | -14.3% | 6.3% | ||
| Q4 24 | -121.2% | 26.6% | ||
| Q3 24 | -5.4% | 19.5% | ||
| Q2 24 | -2.3% | 20.7% | ||
| Q1 24 | -17.3% | 21.3% |
| Q4 25 | $-0.45 | $2.30 | ||
| Q3 25 | $-0.10 | $1.84 | ||
| Q2 25 | $-0.01 | $1.34 | ||
| Q1 25 | $-0.54 | $0.39 | ||
| Q4 24 | $-4.69 | $2.10 | ||
| Q3 24 | $-0.21 | $1.34 | ||
| Q2 24 | $-0.09 | $1.41 | ||
| Q1 24 | $-0.60 | $1.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.3B |
| 总债务越低越好 | — | $617.4M |
| 股东权益账面价值 | $2.4B | $6.0B |
| 总资产 | $5.9B | $41.3B |
| 负债/权益比越低杠杆越低 | — | 0.10× |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $2.3B | ||
| Q3 25 | $1.0B | $3.2B | ||
| Q2 25 | $858.4M | $1.9B | ||
| Q1 25 | $786.2M | $2.7B | ||
| Q4 24 | $1.0B | $2.6B | ||
| Q3 24 | $1.0B | $1.9B | ||
| Q2 24 | $946.8M | $2.6B | ||
| Q1 24 | $652.1M | $3.4B |
| Q4 25 | — | $617.4M | ||
| Q3 25 | — | $617.2M | ||
| Q2 25 | — | $617.0M | ||
| Q1 25 | — | $616.8M | ||
| Q4 24 | — | $616.6M | ||
| Q3 24 | — | $616.4M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $2.4B | $6.0B | ||
| Q3 25 | $2.5B | $5.8B | ||
| Q2 25 | $2.5B | $5.6B | ||
| Q1 25 | $2.4B | $5.5B | ||
| Q4 24 | $2.4B | $5.7B | ||
| Q3 24 | $3.2B | $5.6B | ||
| Q2 24 | $3.2B | $5.4B | ||
| Q1 24 | $3.1B | $5.3B |
| Q4 25 | $5.9B | $41.3B | ||
| Q3 25 | $5.9B | $41.7B | ||
| Q2 25 | $5.8B | $39.9B | ||
| Q1 25 | $5.7B | $40.4B | ||
| Q4 24 | $5.9B | $39.9B | ||
| Q3 24 | $6.7B | $38.9B | ||
| Q2 24 | $6.7B | $37.8B | ||
| Q1 24 | $6.4B | $38.3B |
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $382.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $369.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 32.7% |
| 资本支出强度资本支出/营收 | 3.6% | 1.2% |
| 现金转化率经营现金流/净利润 | — | 1.45× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $1.1B |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $382.4M | ||
| Q3 25 | $219.9M | $338.3M | ||
| Q2 25 | $89.0M | $607.5M | ||
| Q1 25 | $30.8M | $-211.2M | ||
| Q4 24 | $47.1M | $694.6M | ||
| Q3 24 | $138.7M | $198.3M | ||
| Q2 24 | $107.1M | $207.2M | ||
| Q1 24 | $-82.3M | $-609.7M |
| Q4 25 | $120.4M | $369.0M | ||
| Q3 25 | $190.0M | $321.1M | ||
| Q2 25 | $46.7M | $592.7M | ||
| Q1 25 | $-365.0K | $-227.8M | ||
| Q4 24 | $10.7M | $677.2M | ||
| Q3 24 | $112.6M | $185.6M | ||
| Q2 24 | $71.2M | $173.3M | ||
| Q1 24 | $-120.0M | $-619.4M |
| Q4 25 | 13.7% | 32.7% | ||
| Q3 25 | 22.3% | 33.4% | ||
| Q2 25 | 5.8% | 70.6% | ||
| Q1 25 | -0.1% | -27.0% | ||
| Q4 24 | 1.5% | 73.9% | ||
| Q3 24 | 15.9% | 22.9% | ||
| Q2 24 | 10.2% | 21.7% | ||
| Q1 24 | -18.8% | -80.6% |
| Q4 25 | 3.6% | 1.2% | ||
| Q3 25 | 3.5% | 1.8% | ||
| Q2 25 | 5.2% | 1.8% | ||
| Q1 25 | 4.4% | 2.0% | ||
| Q4 24 | 5.1% | 1.9% | ||
| Q3 24 | 3.7% | 1.6% | ||
| Q2 24 | 5.1% | 4.2% | ||
| Q1 24 | 5.9% | 1.3% |
| Q4 25 | — | 1.45× | ||
| Q3 25 | — | 1.60× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | -3.99× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | 1.25× | ||
| Q1 24 | — | -3.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SF
暂无分部数据
